Romerai D’Amico

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 599 citations · Full text

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 432 citations · Full text

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Cathalijne Post, Stephanie M. de Boer, Melanie Powell et al. · International Journal of Radiation Oncology*Biology*Physics · 2020 · 44 citations · Full text

Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy

Bastiaan G. Wortman, Cathalijne Post, Melanie Powell et al. · International Journal of Radiation Oncology*Biology*Physics · 2021 · 18 citations · Full text

High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses – 14 years of single-centre experience

Carlo Pietro Soatti, D. Delishaj, Romerai D’Amico et al. · Journal of Contemporary Brachytherapy · 2020 · 14 citations · Full text